CDNA

NEUTRALM&A

CareDx, Inc.

2026-10-01

Price

$66.23

+1.89%

This is the 2026-10-01 snapshot — the signals and analysis for CDNA as of this single trading day.

View full CDNA research hub →

Score1.1Noise

Signals4/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.5xvs 20d avg

Analysis

CareDx (CDNA) is exhibiting textbook High-Conviction Price Discovery, fueled by the $171 million cash closing of its lab products divestiture to Eurobio Scientific and the recent finalization of Medicare coverage for its core transplant tests. Supported by PERFECT_STACK and MARKET_LEADER signals, the stock is breaking out to 52-week highs as it concentrates entirely on its high-margin U.S. precision medicine business. In the current RISK_ON macro regime, where tight credit spreads and stable volatility encourage aggressive bidding on fundamentally derisked growth stories, CDNA's structural turnaround is being heavily rewarded.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: The combination of Medicare coverage finalization and the $171M all-cash divestiture provides a massive capital injection while stripping away regulatory overhang, driving the stock's 33.5% monthly breakout.
Key Risk: The divestiture removes CareDx's international lab products operations, leaving the company heavily reliant on U.S. testing and digital services to support revenue and margins.
What to Watch: Monitor the stock's ability to hold the $49.86 line-in-the-sand support level as the market digests the recent 340% 1-year run-up.

← Back to 2026-10-01 View Full CDNA History →Yahoo Finance &nearr;